Switzerland (CH)

COVID-19 Vaccination-related Short-term Adverse Events in Patients with Idiopathic Inflammatory Myositis and Autoimmune Multimorbidity: Results from the COVID-19 Vaccination in Autoimmune Diseases Survey (2022) Dey M, Naveen R, Nikiphorou E, Sen P, Lilleker JB, Agarwal V, Kardes S, et al. Conference contribution Abatacept Significantly Reduces Subclinical Inflammation During Treatment (6 Months), This Persists After Discontinuation (12 Months), Resulting in a Delay in the Clinical Development of RA in Patients at Risk of RA (The ARIAA Study) (2022) Rech J, Kleyer A, Ostergaard M, Hagen M, Mendez LV, Tascilar K, Krönke G, et al. Conference contribution 3-years Safety and Efficacy Outcomes of Canakinumab Treatment in Cryopyrin-associated Periodic Syndromes (CAPS) - Data from the RELIANCE Registry (2022) Kuemmerle-Deschner JB, Kortus-Goetze B, Oommen PT, Janda A, Rech J, Schuetz C, Kallinich T, et al. Conference contribution How Well Does Ultrasound-assessed Synovitis in Reduced Joint Sets Predict the Response to Secukinumab in Patients with Active Psoriatic Arthritis and Inadequate Response to Conventional DMARDs? - Exploratory Results from a Phase 3b Study (2022) D'Agostino MA, Conaghan PG, Gaillez C, Naredo E, Mandl P, Carron P, Senolt L, et al. Conference contribution BISPECIFIC ANTIBODIES ENABLE SYNTHETIC AGONISTIC RECEPTOR T CELL THERAPY IN MELANOMA (2022) Benmebarek M, Maerkl F, Keyl J, Cadilha B, Geiger M, Karches C, Obeck H, et al. Conference contribution Auswirkungen eines verkurzten Dosierungsintervalls von Lanreotid-Autogel (LAN) auf die Tumorwachstumsrate ( TGR) bei Patienten mit fortgeschrittenen Neuroendokrinen Tumoren (NETs) in der prospektiven, einarmigen, Phase 2 Studie CLARINET FORTE (2022) Pape UF, Dromain C, Cwikla JB, Lombard-Bohas C, Borbath I, Shah T, Capdevilla J, et al. Conference contribution Trial in Progress: eine multizentrische Open-label Phase IB/ II Studie zur Bestimmung der Dosierung und Sicherheit von Asciminib bei padiatrischen Patienten mit chronischer myeloischer Leukamie in der chronischen Phase (ASC4kids) (2022) Metzler M, Escherich G, Reinhardt D, Kapoor S, Hoch M, Descamps L, Bayar MA, et al. Conference contribution Clinical Performance of the Consensus Immunoscore in Colon Cancer in the Asian Population from the Multicenter International SITC Study (2022) Mlecnik B, Torigoe T, Bindea G, Popivanova B, Xu M, Fujita T, Hazama S, et al. Journal article Effectiveness and Safety of Dabrafenib and Trametinib in Patients with BRAFV600 Mutated Metastatic Melanoma in the Real-World Setting - Final Results of the Non-Interventional COMBI-r Study (2022) Berking C, Livingstone E, Weichenthal M, Leiter-Stoeppke U, Remy J, Eigentler T, Mohr P, et al. Conference contribution Patient preferences of German and Swiss melanoma patients with regard to life-threatening side effects in the context of adjuvant immunotherapy - a qualitative GerMelaTox-A substudy (2022) Peters W, Maul LV, Huning S, Hassel JC, Heinzerling L, Loquai C, Gutzmer R, et al. Conference contribution